Publications:

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Molecular Therapy. Methods & Clinical Development

Samelson-Jones, Benjamin J BJ; Arruda, Valder R VR

Publication Date: 2019-03-15

Variant appearance in text: PC: I16L

PubMed Link: 30705923

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.

Nature Communications

Verhoef, Daniël D; Visscher, Koen M KM; Vosmeer, C Ruben CR; Cheung, Ka Lei KL; Reitsma, Pieter H PH; Geerke, Daan P DP; Bos, Mettine H A MHA

Publication Date: 2017-09-13

Variant appearance in text: PC: I16L

PubMed Link: 28904343

Variant Present in the following documents:

• Main text
• 41467_2017_Article_647.pdf

View BVdb publication page

Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.

Blood

Bunce, Matthew W MW; Toso, Raffaella R; Camire, Rodney M RM

Publication Date: 2011-01-06

Variant appearance in text: PC: I16L

PubMed Link: 20864578

Variant Present in the following documents:

• Main text

View BVdb publication page